|
|
Post by neil36 on Oct 14, 2020 6:28:47 GMT -5
Posted on Stocktwits this morning by Lemonhead:
MannKind Corporation (MNKD) Buy, $4 PT
A Broadened Technosphere Platform Appears to be Emerging, as Inhaled Technosphere Imatinib for PAH Could Be in the Works - BTIG
|
|
|
|
Post by peppy on Oct 14, 2020 6:46:35 GMT -5
Posted on Stocktwits this morning by Lemonhead: MannKind Corporation (MNKD) Buy, $4 PT A Broadened Technosphere Platform Appears to be Emerging, as Inhaled Technosphere Imatinib for PAH Could Be in the Works - BTIG IMATINIB www.hcp.novartis.com/products/gleevec/gleevechcp/Indication GLEEVEC® (imatinib mesylate) tablets are indicated for: • Newly diagnosed adult and pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase • Patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha therapy • Adult patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) • Pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy • Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements as determined with an FDA-approved test • Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-KIT mutation as determined with an FDA-approved test or with c-KIT mutational status unknown • Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown • Adult patients with unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (DFSP) • Patients with KIT (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) • Adjuvant treatment of adult patients following complete gross resection of
KIT (CD117)-positive GIST Frequently reported adverse reactions (all grades) in the 7 MDS/MPD patients assessed were nausea (57%); diarrhea and muscle cramps (43% each); anemia, fatigue, arthralgia, and periorbital edema (29% each) |
|
|
|
Post by cjm18 on Oct 14, 2020 8:34:58 GMT -5
Posted on Stocktwits this morning by Lemonhead: MannKind Corporation (MNKD) Buy, $4 PT A Broadened Technosphere Platform Appears to be Emerging, as Inhaled Technosphere Imatinib for PAH Could Be in the Works - BTIG Same price target as before. Lol these guys are allowed to manipulate the stock price. Better to follow their lead. |
|
|
|
Post by cjm18 on Oct 14, 2020 8:40:33 GMT -5
|
|
|
|
Post by helmut8056 on Oct 14, 2020 9:36:15 GMT -5
All these new inhaler concepts being introduced via support from BF companies while we rest and grow.
|
|
|
|
Post by morfu on Oct 14, 2020 14:11:23 GMT -5
Posted on Stocktwits this morning by Lemonhead: MannKind Corporation (MNKD) Buy, $4 PT A Broadened Technosphere Platform Appears to be Emerging, as Inhaled Technosphere Imatinib for PAH Could Be in the Works - BTIG Same price target as before. Lol these guys are allowed to manipulate the stock price. Better to follow their lead. Hmm you are quite correct and as I said before such a price target makes no sense without discussions of the assumptions and time frame leading to this number. Or is it just something like "I found some good information bite, so lets double the current suppressed share price and make it a nice round number"?
|
|
|
|
Post by cjm18 on Oct 14, 2020 15:12:38 GMT -5
Same price target as before. Lol these guys are allowed to manipulate the stock price. Better to follow their lead. Hmm you are quite correct and as I said before such a price target makes no sense without discussions of the assumptions and time frame leading to this number. Or is it just something like "I found some good information bite, so lets double the current suppressed share price and make it a nice round number"?
I’m sure they have logic in their full report. But there’s a conflict of interest as mannkind needs to raise money and btig can help. |
|
|
|
Post by rfogel on Oct 17, 2020 7:09:01 GMT -5
Where did the imatinib/technosphere idea come from? There's nothing on the Mannkind website. I did find it mentioned in a 10-K from 2008 but in the context of one of many cancer therapies. Does the company plan on advancing any of the pipeline in the foreseeable future? The pipeline page has been pretty static since I first looked at it a about a year ago.
|
|
|
|
Post by goyocafe on Oct 17, 2020 7:31:44 GMT -5
Where did the imatinib/technosphere idea come from? There's nothing on the Mannkind website. I did find it mentioned in a 10-K from 2008 but in the context of one of many cancer therapies. Does the company plan on advancing any of the pipeline in the foreseeable future? The pipeline page has been pretty static since I first looked at it a about a year ago. I think I read there was an off label application for PAH, so maybe something to do with United. Good luck in your search for the truth. |
|
